DULCOLAX - Medsafe
Stimulant laxatives including DULCOLAX do not help with weight loss. Before you use DULCOLAX When you must not use DULCOLAX Do not use DULCOLAX if you are allergic to bisacodyl or any of the other ingredients in DULCOLAX. All the ingredients in DULCOLAX tablets and DULCOLAX suppositories are listed under Product Description.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
DSM-5 Diagnoses and New ICD-10-CM Codes
www.psychiatry.orgOther or Unspecified Stimulant Use Disorder, Mild F15.10 F15.10 Other or Unspecified Stimulant Use Disorder, Mild, In early or sustained remission F15.10 F15.11 Other or Unspecified Stimulant Use Disorder, Moderate F15.20 F15.20 Other or Unspecified Stimulant Use Disorder, Moderate, In early or sustained remission F15.20 F15.21
Counselor’s Family Education Manual
store.samhsa.govWith Stimulant Use Disorders Approach and Package The Matrix Intensive Outpatient Treatment for People With Stimulant Use Disorders (IOP) pack-age provides a structured approach for treating adults who abuse or are dependent on stimulant drugs. The approach followed in the treatment package was developed by the Matrix Institute in
SUBSTANCE USE DISORDERS - NMHIMA
nmhima.orgSTIMULANT USE DISORDER • A problematic pattern of amphetamine-type substance, cocaine, or other stimulant use leading to clinically significant impairment or distress, manifested by at least 2 of the criteria outlined in slides 4 -7, within a 12 month period . • Mild: Presence of 2 -3 symptoms • -305.70 (F15.10) Amphetamine -type
DSM-5 Substance Use Diagnosis ICD-10 Code Severity …
publichealth.lacounty.govStimulant Use Disorder- Amphetamine-Type Substance MILD Methamphetamine (crystal meth, crank, speed, tweek, glass, etc.) F15.10 MODERATE F15.20 SEVERE F15.20 Stimulant Use Disorder- Cocaine MILD Cocaine (coke, blow, snow, etc.) F14.10 MODERATE F14.20 SEVERE F14.20 Sedative, Hypnotic, or Anxiolytic Use Disorder MILD Benzodiazepines (Xanax ...
Diagnosis, Substance, Stimulant, Dsm 5 substance use diagnosis, Stimulant use
DIAGNOSIS REFERENCE GUIDE A. Diagnostic Criteria for ...
cchealth.orgStimulant Use Disorder Mild: Presence of 2-3 symptoms 305.70 (F15.10) Amphetamine-type substance 305.60 (F14.10) Cocaine 305.70 (F15.10) Other or unspecified stimulant Moderate: Presence of 4-5 symptoms 304.40 (F15.20) Amphetamine-type …
the side effects of common psychiAtric drugs
www.cchr.orgA stimulant (psychostimulant) refers to any mind-altering chemical or substance that affects the central nervous system by speeding up the body’s functions, including the heart and breathing rates. Stimulants are most often prescribed to children for the so …
FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED …
www.dhs.wisconsin.govIf yes, list the methylphenidate stimulant, dose, dosage adjustments, specific details about the unsatisfactory therapeutic response, and the approximate dates that the methylphenidate stimulant was taken in the space provided. 16. Has the member taken a methylphenidate stimulant and experienced a clinically
Stimulant and Related Medications: Use in Adults
www.cms.govassociation between the use of stimulant medications and adverse cardiovascular events. However, the FDA encourages periodic monitoring of heart rate and blood pressure and encourages avoiding the use of stimulant medications in patients with serious heart problems. Two more studies in adults are being reviewed to evaluate
Medication, Related, Adults, Stimulant, Use in adults, Stimulant and related medications